Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca Faces 'Key Pressures' But $45bn Sales Target 'Still Achievable'

This article was originally published in Scrip

Executive Summary

AstraZeneca's business is under two key pressures as it enters 2016, CEO Pascal Soriot explained during the company's fourth quarter and full year 2015 presentation: the "enormous headwinds" created by the US patent expiry of Crestor this year and the dilutive effect of the ZS Pharma and Acerta Pharma acquisitions. AstraZeneca reported fourth quarter and full-year numbers broadly in-line with expectations, meeting guidance for 2015.


Related Content

4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds